Cargando…
Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion()()
Glioblastoma is known to secrete high levels of vascular endothelial growth factor (VEGF), and clinical studies with bevacizumab, a monoclonal antibody to VEGF, have demonstrated convincing therapeutic benefits in glioblastoma patients. However, its induction of invasive proliferation has also been...
Autores principales: | Ishida, Joji, Onishi, Manabu, Kurozumi, Kazuhiko, Ichikawa, Tomotsugu, Fujii, Kentaro, Shimazu, Yosuke, Oka, Tetsuo, Date, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101347/ https://www.ncbi.nlm.nih.gov/pubmed/24704537 http://dx.doi.org/10.1016/j.tranon.2014.02.016 |
Ejemplares similares
-
Gene expression profiling of the anti-glioma effect of Cilengitide
por: Onishi, Manabu, et al.
Publicado: (2013) -
Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis
por: Hattori, Yasuhiko, et al.
Publicado: (2022) -
A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy
por: Oka, Tetsuo, et al.
Publicado: (2016) -
Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013) -
Phenotypic Transition as a Survival Strategy of Glioma
por: ICHIKAWA, Tomotsugu, et al.
Publicado: (2016)